- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02177435
Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension
July 7, 2014 updated by: Boehringer Ingelheim
An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg.
Study to demonstrate that a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide (HCTZ) 12.5 mg (FDC 80/12.5) is superior to telmisartan 80 mg (Telm 80) alone in patients who failed to respond adequately to Telm 80 monotherapy in lowering seated trough diastolic blood pressure (DBP) after eight weeks of treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
491
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- History of mild-to-moderate hypertension
- Patients who fail to respond adequately to telmisartan monotherapy
- Participants between 18 and 80 years of age
- Ability to provide written informed consent
Exclusion Criteria:
- Patients taking more than three anti-hypertensive medications at the screening visit
Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening)
- Who are not surgically sterile (hysterectomy, tubal ligation)
- Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study
Any women:
- Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 4)
- Who is nursing
Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
- Serum creatinine > 2.3 mg/dL
- Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline
- Known or suspected secondary hypertension
- Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
- Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV)
- Unstable angina within the past three months
- Stroke within the past six months
- Myocardial infarction or cardiac surgery within the past three months
- PTCA (percutaneous transluminal coronary angioplasty) within the past three months
- History of angioedema
- Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
- Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
- Administration of digoxin or other digitalis-type drugs
- Patients with insulin treated Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
- Known drug or alcohol dependency within the past one year period
- Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
- Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
- Known hypersensitivity to any component of the formulations
- Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Telmisartan plus Hydrochlorothiazide
|
|
EXPERIMENTAL: Telmisartan
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in seated diastolic blood pressure (DBP) at trough
Time Frame: Baseline (day 0), day 28, day 56
|
Baseline (day 0), day 28, day 56
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients with adverse events
Time Frame: up to 16 weeks
|
up to 16 weeks
|
Change from baseline in seated systolic blood pressure (SBP) at trough
Time Frame: Baseline (day 0), day 28, day 56
|
Baseline (day 0), day 28, day 56
|
Change from baseline in standing DBP and SBP at trough
Time Frame: Baseline (day 0), day 28, day 56
|
Baseline (day 0), day 28, day 56
|
Blood pressure control (seated DBP < 90 mmHg)
Time Frame: 16 weeks
|
16 weeks
|
Systolic blood pressure response
Time Frame: 16 weeks
|
16 weeks
|
Number of patients with abnormal findings in physical examination
Time Frame: Baseline (screening), day 0 and day 56
|
Baseline (screening), day 0 and day 56
|
Changes from baseline in heart rate
Time Frame: Baseline (screening), day -56, -28, 0, 28 and 56
|
Baseline (screening), day -56, -28, 0, 28 and 56
|
Number of patients with abnormal changes in laboratory parameters
Time Frame: Baseline (screening), day 0 and day 56
|
Baseline (screening), day 0 and day 56
|
Number of patients with abnormal changes in resting 12-lead ECG (electrocardiogram)
Time Frame: Baseline (screening), day 0 and day 56
|
Baseline (screening), day 0 and day 56
|
Orthostatic changes in blood pressure
Time Frame: Baseline (screening), day -56, -28, 0, 28 and 56
|
Baseline (screening), day -56, -28, 0, 28 and 56
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 1999
Primary Completion (ACTUAL)
September 1, 1999
Study Registration Dates
First Submitted
June 26, 2014
First Submitted That Met QC Criteria
June 26, 2014
First Posted (ESTIMATE)
June 27, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
July 8, 2014
Last Update Submitted That Met QC Criteria
July 7, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Hydrochlorothiazide
- Telmisartan
- Telmisartan, hydrochlorothiazide drug combination
Other Study ID Numbers
- 502.261
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States